Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Steven Coutre, Johannes Schetelig, Sebastian Böttcher, Mehrdad Mobasher, Sari H. Enschede, Michael Hallek, Rod A. Humerickhouse, Talha Munir, John F. Seymour, Soham D. Puvvada, Maria Verdugo, Brenda Chyla, Andrew W. Roberts, Wojciech Jurczak, Gary Gordon, Clemens M. Wendtner, Ming Zhu, Barbara Eichhorst, Elisa Cerri, Monali Desai, William G. Wierda, Stephen P. Mulligan, Stephan Stilgenbauer
Publikováno v:
The Lancet Oncology. 17:768-778
Summary Background Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-molecule BCL2 inhibitor that induces chron
Autor:
Julia Alexeeva, José Cabeçadas, Franck Morschhauser, Tsvetan Biyukov, Thierry Lamy, Elias Campo, Sprint Trial Investigators, Jan Walewski, Stefano Pileri, Marek Trnĕný, John Radford, Jiri Mayer, Wojciech Jurczak, Marie-Laure Casadebaig Bravo, Luca Arcaini, David Belada, Meera Patturajan, Simon Rule
Publikováno v:
British Journal of Haematology
British Journal of Haematology, 2018, British journal of haematology, 180, pp.224-235. ⟨10.1111/bjh.15025⟩
Arcaini, L, Lamy, T, Walewski, J, Belada, D, Mayer, J, Radford, J & Jurcak, W 2017, ' Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. ', British Journal of Haematology . https://doi.org/10.1111/bjh.15025
British Journal of Haematology, 2018, British journal of haematology, 180, pp.224-235. ⟨10.1111/bjh.15025⟩
Arcaini, L, Lamy, T, Walewski, J, Belada, D, Mayer, J, Radford, J & Jurcak, W 2017, ' Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. ', British Journal of Haematology . https://doi.org/10.1111/bjh.15025
International audience; In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93f3601d71267234a5a6fc004aa59db
https://hal.univ-lille.fr/hal-03196163
https://hal.univ-lille.fr/hal-03196163
Autor:
Heidi Mocikova, Agnieszka Giza, Mariajose Lechuga, Alessandra Romano, Joseph Boni, Sundra Ramanathan, Jill S. Clancy, Georg Hess, Pratyush Giri, Wojciech Jurczak, Michelle Casey
Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8815e6543b0760354707c48c66a8184
https://ruj.uj.edu.pl/xmlui/handle/item/93991
https://ruj.uj.edu.pl/xmlui/handle/item/93991
Autor:
Jin Seok Kim, Michinori Ogura, Dzhelil Osmanov, Mariana Vasilica, Christian Buske, Sang Joon Lee, Edvard Zhavrid, Rajinish Nagarkar, Yun Ju Bae, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Sungyoung Lee, Bertrand Coiffier, Aliaksandr Prokharau, Juan-Manuel Sancho, Larry W. Kwak
Publikováno v:
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-in
Autor:
Eugen Tausch, Marco Montillo, Lukas Smolej, David Simpson, Árpád Illés, Franck Morschhauser, Yeonhee Kim, Jacqueline C. Barrientos, Paolo Ghia, Peter Hillmen, Miklos Egyed, Paula Marlton, Tadeusz Robak, Jeff P. Sharman, Julio Delgado, Andrew D. Zelenetz, Adeboye H. Adewoye, Jennifer R. Brown, Alexander S. Pristupa, Wojciech Jurczak, Lyndah Dreiling, Stephan Stilgenbauer, Bertrand Coiffier
Publikováno v:
Lancet Oncology
Lancet Oncology, 2017, The Lancet Oncology, 18 (3), pp.297-311. ⟨10.1016/S1470-2045(16)30671-4⟩
Lancet Oncology, 2017, The Lancet Oncology, 18 (3), pp.297-311. ⟨10.1016/S1470-2045(16)30671-4⟩
International audience; BACKGROUND: Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ae883d6b2873d39c62a36455b8021d
https://hal.univ-lille.fr/hal-03552376/file/nihms889304.pdf
https://hal.univ-lille.fr/hal-03552376/file/nihms889304.pdf
Autor:
Jenna D. Goldberg, Martin Dreyling, Cristina João, Wenjiong Zhou, Christopher Enny, Shana Traina, Simon Rule, Mathias Witzens-Harig, Isabelle Bence-Bruckler, Jessica Vermeulen, Joris Diels, Chiun Fang Chiou, Wojciech Jurczak, Mats Jerkeman, Chiara Rusconi, Seok-Goo Cho, Cristina Trambitas, Georg Hess, Rodrigo Santucci Silva, Dolores Caballero
Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651c50264405947b4c6a9d725803ca10
https://ruj.uj.edu.pl/xmlui/handle/item/116501
https://ruj.uj.edu.pl/xmlui/handle/item/116501
Autor:
Andre Goy, Peter Martin, Kristie A. Blum, John Radford, Lori Kunkel, Ranjana H. Advani, Brad S. Kahl, Rebecca Auer, Bożena Jachimczak, Michael D. Williams, Stephan Stilgenbauer, Michael L. Wang, Agnieszka Giza, Jorge Romaguera, Wiktor Jędrzejczak, Jacqueline C. Barrientos, Fong Clow, Darrin M. Beaupre, Wojciech Jurczak, Jesse McGreivy, Simon Rule, Ewa Chmielowska
Publikováno v:
Acta Haematologica Polonica. 44:314-318
Bruton's tyrosine kinase (BTK) is a central mediator of B-cell receptor (BCR) signaling essential for normal B-cell development. Ibrutinib is an oral BTK inhibitor that induces apoptosis and inhibits migration and adhesion of malignant B-cells. Updat
Autor:
Steven Sun, Mats Jerkeman, Simon Rule, Georg Hess, John Bothos, Isabelle Bence-Bruckler, Mathias Witzens-Harig, Nibedita Bandyopadhyay, Fritz Offner, Christopher Enny, Jessica Vermeulen, Dolores Caballero, Aleksandra Rizo, Shana Traina, Sriram Balasubramanian, Chiara Rusconi, Martin Dreyling, Cristina João, Seok-Goo Cho, Rodrigo Santucci Silva, Jenna D. Goldberg, Marek Trneny, Wojciech Jurczak
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f3968cb14298604d326493927a7acf
https://ruj.uj.edu.pl/xmlui/handle/item/117399
https://ruj.uj.edu.pl/xmlui/handle/item/117399
Autor:
David Belada, Boris V. Afanasyev, Jiri Mayer, Agnieszka Giza, Simon Rule, Marek Trněný, Kazimierz Kuliczkowski, Julia Alexeeva, Antoine Thyss, Lorenz Trümper, Tsvetan Biyukov, Franck Morschhauser, Wojciech Jurczak, John Radford, Jan Walewski, Caterina Stelitano, K. D. Kaplanov, Sergey Voloshin, Marie Laure Casadebaig Bravo, Reinhard Marks, Meera Patturajan, Noel Milpied, Thierry Lamy, Alexej Kuzmin, Luca Arcaini
Publikováno v:
Lancet Oncology
Lancet Oncology, 2016, 17 (3), pp.319-331. ⟨10.1016/S1470-2045(15)00559-8⟩
Lancet Oncology, Elsevier, 2016, 17 (3), pp.319-331. ⟨10.1016/S1470-2045(15)00559-8⟩
Lancet Oncology, 2016, 17 (3), pp.319-331. ⟨10.1016/S1470-2045(15)00559-8⟩
Lancet Oncology, Elsevier, 2016, 17 (3), pp.319-331. ⟨10.1016/S1470-2045(15)00559-8⟩
Summary Background Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in relapsed or refractory mantle cell lymphoma. The aim of this randomised study was to examine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1065b44f53f1ba835dc02b6ccf52d215
https://doi.org/10.1016/S1470-2045(15)00559-8
https://doi.org/10.1016/S1470-2045(15)00559-8
Autor:
Michael E. Williams, Stephen E. Spurgeon, Ewa Chmielowska, Michael L. Wang, Dana Lee, John Radford, Darrin M. Beaupre, Andre Goy, Jorge E. Romaguera, Liang Zhang, Kristie A. Blum, Peter Johnson, Linda Baher, Martin Dreyling, Simon Rule, Jacqueline C. Barrientos, Peter Martin, Stephan Stilgenbauer, Wiesław Wiktor Jędrzejczak, Brad S. Kahl, Mei Cheng, Rebecca Auer, Ranjana H. Advani, Wojciech Jurczak
Publikováno v:
Wang, M L, Blum, K A, Martin, P, Goy, A, Auer, R, Kahl, B S, Jurczak, W, Advani, R H, Romaguera, J E, Williams, M E, Barrientos, J C, Chmielowska, E, Radford, J, Stilgenbauer, S, Dreyling, M, Jedrzejczak, W W, Johnson, P, Spurgeon, S E, Zhang, L, Baher, L, Cheng, M, Lee, D, Beaupre, D M & Rule, S 2015, ' Long-term follow-up of MCL patients treated with single-agent ibrutinib : Updated safety and efficacy results ', Blood, vol. 126, no. 6, pp. 739-745 . https://doi.org/10.1182/blood-2015-03-635326
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. We report the updated safety and efficacy results from the multicenter, open-label phase 2 registrat